storage comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
=== Belief === Morea was raised in a Roman Catholic household and has openly celebrated Christian festivals such as Easter with his family. In 2023, Morea was invited among several members of India's Christian community to a Christmas celebration hosted by Prime Minister Narendra Modi at his official residence in New Delhi.
AlphaFold 2 scoring more than 90 in CASP's global distance test (GDT) was considered a great achievement in computational biology. Nobel Prize winner and structural biologist Venki Ramakrishnan called the result "a stunning advance on the protein folding problem", adding that "It has occurred decades before many people in the field would have predicted. It will be exciting to see the many ways in which it will fundamentally change biological research." AlphaFold 2's success received wide media attention. News pieces appeared in the science press, such as Nature, Science, MIT Technology Review, and New Scientist, and the story was covered by national newspapers. A frequent theme was the ability to predict protein structures based on the constituent amino acid sequence, expected to have benefits in the life sciences—accelerating drug discovery and enabling better understanding of diseases. Some have noted that even a perfect answer to the protein prediction problem still leaves questions about the protein folding problem (and thus protein dynamics)—understanding in detail how the folding process actually occurs in nature (and how sometimes they can also misfold).
Profilin was first described by Lars Carlsson in the lab of Uno Lindberg and co-workers in the early 1970s as the first actin monomer binding protein. It followed the realization that not only muscle, but also non-muscle cells, contained high concentrations of actin, albeit in part in an unpolymerized form. Profilin was then believed to sequester actin monomers (keep them in a pro-filamentous form), and release them upon a signal to make them accessible for fast actin polymer growth.
Beano is an enzyme-based dietary supplement that is used to reduce gas in the digestive tract, thereby improving digestion and reducing bloating, discomfort, and flatulence caused by gas. It contains the enzyme alpha-galactosidase (α-GAL). It was introduced as a liquid, but that has been discontinued and it is now available only as tablets and strawberry-flavored "Meltaways". Beano is marketed and distributed by Prestige Consumer Healthcare, Inc.
Sources: en.wikipedia.org
10 July Dynamic shell formation is demonstrated experimentally for the first time. Researchers claim their technique is a feasible target for mass production of fusion energy. The highest albedo ever measured for an exoplanet is confirmed using data from the CHEOPS space telescope. The ultra-hot Neptune LTT 9779 b is shown to reflect 80% of incoming light from its star (compared to 75% for Venus), due to the high metal content of its clouds. 11 July Three possible "dark star" candidates are reported, at times ranging from about 320 million to 400 million years after the Big Bang, based on analysis of observations by the James Webb Space Telescope Berkeley Earth reports that June 2023 was the warmest June since records began in 1850, and broke the previous record by 0.18 °C. Its temperature dataset suggests that 2023 is now 81% likely to become a new record year for global warming. A study suggests that carbon taxation approaches or instruments would be more effective and fairer when distinguishing between luxury- and basic goods and services. A separate study (17 July) finds that for energy demand reduction (EDR), "capping energy use of the top quintile of consumers" would be effective, more equitable, and increase public acceptance of transformative climate action in Europe. 12 July Astronomers report considerable success of the James Webb Space Telescope (JWST) after its first year of operations.
The Ghana Stock Exchange is the fifth largest on continental Africa and third largest in sub-Saharan Africa, having a market capitalisation of GH¢ 57.2 billion or CN¥180.4 billion in 2012, with the South Africa JSE Limited ranked first. The Ghana Stock Exchange was the second best performing stock exchange in Sub-Saharan Africa in 2013. Ghana produces cocoa. It is the second largest producer of cocoa globally and its ICCO membership helps in its international cocoa trade. Ghana is classified as a middle-income country. Services account for 50% of GDP, followed by manufacturing (24.1%), extractive industries (5%), and taxes (20.9%). Ghana's economy is characterized by a growing manufacturing sector and the export of digital technology products. The country is also engaged in the assembly and export of automobiles and ships. Ghana's economy benefits from a range of resource-rich exports, including industrial minerals and agricultural products, with cocoa being a primary commodity. The nation is a producer and exporter of petroleum and natural gas. The information and communications technology (ICT) sector plays a role in Ghana's industrial landscape, with companies such as Rlg Communications, a state-affiliated digital technology corporation, leading in the production of tablet computers, smartphones, and consumer electronics. Urban electric cars have been manufactured in Ghana since 2014. Ghana announced plans to issue government debt by way of social and green bonds in autumn of 2021, making it the first African country to do so.
Drugs in treating nipple ache during breastfeeding can be divided into two categories based on the ways of administration: topical application and oral medication. The table below summarises the common medicine that can be taken by patients.
Sources: en.wikipedia.org
The Diabetes Research in Children Network Study Group observed blood sugar levels decrease rapidly in the first 15 minutes of exercise and continue to drop during the 75-minute session. The Diabetes Research Group also found that after participating in prolonged aerobic exercise, 83% of participants had at least a 25% decrease in blood sugar levels. High-intensity and concurrent training interventions, strength training, and prolonged aerobic exercise all have been shown to help reduce HbA1c and blood glucose levels in children with type 1 diabetes; therefore, demonstrating that exercise plays a vital role in the management of type 1 diabetes.
==== Cheese ==== Louis de Jaucourt, in the Encyclopédie ou Dictionnaire raisonné des sciences, des arts et des métiers, cites a German who invented a way to make three cheeses, from large potatoes boiled in their skins, then peeled and ground with a spoon before being mixed with curdled milk; the cheeses obtained acquire more quality and finesse as they age. The Encyclopédie Méthodique, which includes this information, specifies the proportions according to which the cheese is intended for the poor (five pounds of vegetables for one pound of curd), for everyone (four pounds for two pounds of curd), or for the best tables (two pounds for four pounds of milk); by adding cream, large cheeses like those of Holland are made. She says that sheep's or goat's milk gives better results than cow's milk.
From summer 1921 to spring 1922, a team at the University of Toronto succeeded in isolating the hormone insulin, which type 1 diabetics are unable to produce on their own. Hughes's mother contacted Canadian doctor Frederick Banting, who agreed to take her as a private patient. Hughes arrived in Toronto with her mother on August 15, 1922, and began receiving insulin from Dr. Banting. She recovered rapidly, and she was placed on a 2200–2400 calorie weight-gain diet within two weeks. She returned home to Washington, D.C., on Thanksgiving Day 1922.
== External links == Osteocalcin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: Q8HYY9 (Pig Osteocalcin) at the PDBe-KB.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.